Key result
Pimobendan is safe, well tolerated, improves quality of life, and reduces mortality in dogs with congestive heart failure secondary to dilated cardiomyopathy.
Why the study?
Does pimobendan improve quality of life and reduce mortality in dogs with congestive heart failure secondary to dilated cardiomyopathy or chronic valvular disease?
Does pimobendan improve quality of life and reduce mortality in dogs with congestive heart failure secondary to dilated cardiomyopathy or chronic valvular disease?
Pimobendan appears to be a safe and effective adjunctive therapy for improving quality of life and reducing mortality in dogs with congestive heart failure.
Answers are grounded in this paper and cite their sources.
Supports adjunctive pimobendan in canine DCM-CHF; hypothesis-generating pending randomized trials.
Pimobendan is a novel agent with properties that are highly desirable in the clinical management of congestive heart failure (CHF) secondary to both dilated cardiomyopathy (DCM) and chronic degenerative valvular disease in dogs. Review of available data suggests that pimobendan is safe, well tolerated, and leads to enhanced quality of life in dogs with CHF secondary to DCM or chronic valvular disease when used in combination with furosemide or other conventional therapies (e.g., angiotensin-converting enzyme inhibitors, digoxin). Pimobendan leads to a reduction in mortality from CHF associated with DCM, and ongoing studies are evaluating its effects on mortality associated with chronic valvular disease.
No takes yet. Share an insight, caveat, or question.
Gordon et al. (2006) conducted a review in Congestive heart failure (CHF) secondary to dilated cardiomyopathy (DCM) and chronic degenerative valvular disease in dogs. Pimobendan was evaluated. Pimobendan is safe, well tolerated, improves quality of life, and reduces mortality in dogs with congestive heart failure secondary to dilated cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: